Hanne-Dorthe Emborg

Hanne-Dorthe Emborg

Auto-generated profile, based on publicly available information

Hanne-Dorthe Emborg

Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2022 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
MGMie Agermose Gram
Mie Agermose Gram
HEHanne-Dorthe Emborg
Hanne-Dorthe Emborg
ASAstrid Blicher Schelde
Astrid Blicher Schelde
NFNikolaj Ulrik Friis
Nikolaj Ulrik Friis
KNKatrine Finderup Nielsen
Katrine Finderup Nielsen
CHChristian Holm Hansen
Christian Holm Hansen
Background: The continued occurrence of more contagious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants and waning immunity over time require ongoing reevaluation of the vaccine effectiveness (VE). This study aimed to estimate the effectiveness in 2 age groups (12 to 59 and 60 years or above) of 2 or 3 vaccine doses (BNT162b2 mRNA or mRNA-1273) by time since vaccination against SARS-CoV-2 infection and Coronavirus Disease 2019 (COVID-19) hospitalization in an Alpha-, Delta-, or Omicron-dominated period. Methods and findings: A Danish nationwide cohort study design was used to estimate VE against SARS-CoV-2 infection and COVID-19 hospitalization with the Alpha, Delta, or Omicron variant. Information was obtained from nationwide registries and linked using a unique personal identification number. The study included all previously uninfected residents in Denmark aged 12 years or above (18 years or above for the analysis of 3 doses) in the Alpha (February 20 to June 15, 2021), Delta (July 4 to November 20, 2021), and Omicron (December 21, 2021 to January 31, 2022) dominated periods. VE estimates including 95% confidence intervals (CIs) were calculated (1-hazard ratio∙100) using Cox proportional hazard regression models with underlying calendar time and adjustments for age, sex, comorbidity, and geographical region. Vaccination status was included as a time-varying exposure. In the oldest age group, VE against infection after 2 doses was 90.7% (95% CI: 88.2; 92.7) for the Alpha variant, 82.3% (95% CI: 75.5; 87.2) for the Delta variant, and 39.9% (95% CI: 26.3; 50.9) for the Omicron variant 14 to 30 days since vaccination. The VE waned over time and was 73.2% (Alpha, 95% CI: 57.1; 83.3), 50.0% (Delta, 95% CI: 46.7; 53.0), and 4.4% (Omicron, 95% CI: −0.1; 8.7) >120 days since vaccination. Higher estimates were observed after the third dose with VE estimates against infection of 86.1% (Delta, 95% CI: 83.3; 88.4) and 57.7% (Omicron, 95% CI: 55.9; 59.5) 14 to 30 days since vaccination. Among both age groups, VE against COVID-19 hospitalization 14 to 30 days since vaccination with 2 or 3 doses was 98.1% or above for the Alpha and Delta variants. Among both age groups, VE against COVID-19 hospitalization 14 to 30 days since vaccination with 2 or 3 doses was 95.5% or above for the Omicron variant. The main limitation of this study is the nonrandomized study design including potential differences between the unvaccinated (reference group) and vaccinated individuals. Conclusions: Two vaccine doses provided high protection against SARS-CoV-2 infection and COVID-19 hospitalization with the Alpha and Delta variants with protection, notably against infection, waning over time. Two vaccine doses provided only limited and short-lived protection against SARS-CoV-2 infection with Omicron. However, the protection against COVID-19 hospitalization following Omicron SARS-CoV-2 infection was higher. The third vaccine dose substantially increased the level and duration of protection against infection with the Omicron variant and provided a high level of sustained protection against COVID-19 hospitalization among the +60-year-olds.

11 January 2024 in Eurosurveillance
Verified
Journal Article
Open access
ANAnne Christine Nordholm
Anne Christine Nordholm
BSBolette Søborg
Bolette Søborg
PJPikka Jokelainen
Pikka Jokelainen
KMKarina Lauenborg Møller
Karina Lauenborg Møller
LSLotte Flink Sørensen
Lotte Flink Sørensen
HEHanne-Dorthe Emborg
Hanne-Dorthe Emborg
We report a surge of patients, especially children and adolescents, with respiratory disease caused byMycoplasma pneumoniaein Denmark since October 2023. While the surge has reached an epidemic level, no impact on hospital capacity has been observed; only 14% (446/3,195) of cases, primarily adults, required hospitalisation. Macrolide resistance was detected in less than 2% of samples tested. Timely monitoring of hospitalisations linked toM. pneumoniaeinfections has been established to inform the healthcare system, decisionmakers and the public.

30 April 2020 in Eurosurveillance
Verified
Journal Article
Open access
JOJessica Ohland
Jessica Ohland
CWCharlotte Warren-Gash
Charlotte Warren-Gash
RBRuth Blackburn
Ruth Blackburn
KMKåre Mølbak
Kåre Mølbak
PVPalle Valentiner-Branth
Palle Valentiner-Branth
HEHanne-Dorthe Emborg
Hanne-Dorthe Emborg
Background: Several studies have investigated a possible association between respiratory infection and acute myocardial infarction (MI). As both influenza and pneumococcal infections are vaccine preventable, understanding the populations affected by virus-induced cardiovascular complications is important to guide public health and clinical practice. Aim: This observational study aimed to quantify the association between laboratory-confirmed respiratory bacteria or virus infections and risk of first MI or stroke, by using self-controlled case series (SCCS) analysis of anonymised linked electronic Danish health records. Methods: The SCCS method was used to determine the relative incidence of the first event of MI and stroke occurring within 28 days after laboratory-confirmed respiratory infections compared with the baseline time period. Results: In the age and season adjusted analyses for first acute MI, the incidence ratios (IR) of a MI event occurring during the risk period were significantly elevated following a Streptococcus pneumoniae infection with values of 20.1, 11.0 and 4.9 during 1–3, 4–7 and 8–14 days, respectively and following respiratory virus infection with values of 15.2, 4.5 and 4.4 during 1–3, 8–14 and 15–28 days, respectively. The significantly elevated IRs for stroke following an S. pneumoniae infection were 25.5 and 6.3 during 1–3 and 8–14 days, respectively and following respiratory virus infection 8.3, 7.8 and 6.2 during 1–3, 4–7 and 8–14 days, respectively. Conclusion: This study suggested a significant cardiovascular event triggering effect following infection with S. pneumoniae and respiratory viruses (mainly influenza), indicating the importance of protection against vaccine-preventable respiratory infections.

22 November 2022 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
KNKatrine Finderup Nielsen
Katrine Finderup Nielsen
IMIda Rask Moustsen-Helms
Ida Rask Moustsen-Helms
ASAstrid Blicher Schelde
Astrid Blicher Schelde
MGMie Agermose Gram
Mie Agermose Gram
HEHanne-Dorthe Emborg
Hanne-Dorthe Emborg
PVPalle Valentiner-Branth
Palle Valentiner-Branth
Background: Individuals with a prior Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection have a moderate to high degree of protection against reinfection, though seemingly less so when the Omicron variant of SARS-CoV-2 started to circulate. The aim of this study was to evaluate the vaccine effectiveness (VE) against SARS-CoV-2 reinfection, Coronavirus Disease 2019 (COVID-19)-related hospitalization, and COVID-19-related death, in individuals with prior SARS-CoV-2 infection, and to assess the effect of time since vaccination during periods with different dominant SARS-CoV-2 variants. Methods and findings: This study used a nationwide cohort design including all individuals with a confirmed SARS-CoV-2 infection, who were alive, and residing in Denmark between 1 January 2020 and 31 January 2022. Using Danish nationwide registries, we obtained information on SARS-CoV-2 infections, COVID-19 vaccination, age, sex, comorbidity, staying at hospital, and country of origin. The study population included were individuals with prior SARS-CoV-2 infection. Estimates of VE against SARS-CoV-2 reinfection with 95% confidence intervals (CIs) were calculated using a Poisson regression model and adjusted for age, sex, country of origin, comorbidity, staying at hospital, calendar time, and test incidence using a Cox regression model. The VE estimates were calculated separately for three periods with different dominant SARS-CoV-2 variants (Alpha (B.1.1.7), Delta (B.1.617.2), or Omicron (B.1.1.529)) and by time since vaccination using unvaccinated as the reference. In total, 148,527 person-years and 44,192 SARS-CoV-2 infections were included for the analysis regarding reinfections. The study population comprised of 209,814 individuals infected before or during the Alpha period, 292,978 before or during the Delta period, and 245,530 before or during the Omicron period. Of these, 40,281 individuals had completed their primary vaccination series during the Alpha period (19.2%), 190,026 during the Delta period (64.9%), and 158,563 during the Omicron period (64.6%). VE against reinfection following any COVID-19 vaccine type administered in Denmark, peaked at 71% (95% CI: -Inf to 100%) at 104 days or more after vaccination during the Alpha period, 94% (95% CI: 92% to 96%) 14 to 43 days after vaccination during the Delta period, and 60% (95% CI: 58% to 62%) 14 to 43 days after vaccination during the Omicron period. Waning immunity following vaccination was observed and was most pronounced during the Omicron period. Due to too few events, it was not possible to estimate VE for hospitalization and death. Study limitations include potentially undetected reinfections, differences in health-seeking behavior, or risk behavior between the compared groups. Conclusions: This study shows that in previously infected individuals, completing a primary vaccination series was associated with a significant protection against SARS-CoV-2 reinfection compared with no vaccination. Even though vaccination seems to protect to a lesser degree against reinfection with the Omicron variant, these findings are of public health relevance as they show that previously infected individuals still benefit from COVID-19 vaccination in all three variant periods.

3 June 2021 in Eurosurveillance
Verified
Journal Article
Open access
HEHanne-Dorthe Emborg
Hanne-Dorthe Emborg
ACAnnaSara Carnahan
AnnaSara Carnahan
KBKaroline Bragstad
Karoline Bragstad
RTRamona Trebbien
Ramona Trebbien
MBMia Brytting
Mia Brytting
LVLasse S Vestergaard
Lasse S Vestergaard
Background: In mid-March 2020, a range of public health and social measures (PHSM) against the then new coronavirus disease (COVID-19) were implemented in Denmark, Norway and Sweden. Aim: We analysed the development of influenza cases during the implementation of PHSM against SARS-CoV-2 in the Scandinavian countries. Method: Based on the established national laboratory surveillance of influenza, we compared the number of human influenza cases in the weeks immediately before and after the implementation of SARS-CoV-2 PHSM by country. The 2019/20 influenza season was compared with the five previous seasons. Results: A dramatic reduction in influenza cases was seen in all three countries, with only a 3- to 6-week duration from the peak of weekly influenza cases until the percentage dropped below 1%. In contrast, in the previous nine influenza seasons, the decline from the seasonal peak to below 1% of influenza-positive samples took more than 10 weeks. Conclusions: The PHSM against SARS-CoV-2 were followed by a dramatic reduction in influenza cases, indicating a wider public health effect of the implemented measures.

14 April 2022 in Eurosurveillance
Verified
Journal Article
Open access
HEHanne-Dorthe Emborg
Hanne-Dorthe Emborg
LVLasse S Vestergaard
Lasse S Vestergaard
ABAmanda Bolt Botnen
Amanda Bolt Botnen
JNJens Nielsen
Jens Nielsen
TKTyra G Krause
Tyra G Krause
RTRamona Trebbien
Ramona Trebbien
We estimated interim influenza A vaccine effectiveness (VE) following a late sharp rise in cases during an influenza A(H3N2)-dominated 2021/22 season, after lifting COVID-19 restrictions. In children aged 2–6 years offered a live attenuated influenza vaccine, adjusted VE was 62.7% (95% CI: 10.9–84.4) in hospitalised and 64.2% (95% CI: 50.5–74.1) in non-hospitalised children. In non-hospitalised patients aged 7–44 years, VE was 24.8% (95% CI: 12.8–35.2); VE was non-significant in remaining age groups and hospital/non-hospital settings.